http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CheolWon Jang,SungHwan Hwang,Tae Kyung Jin,Hyung Jin Shin,Byung-Kyu Cho 대한신경외과학회 2023 Journal of Korean neurosurgical society Vol.66 No.6
Objective : This retrospective study investigated the factors that affect cage obliquity angle despite orthogonal maneuvers performed during oblique lateral interbody fusion (OLIF) and assessed the relationship between cage obliquity angle and radiological outcomes post-surgery. Methods : Twenty-nine males who underwent L4-L5 OLIF for lumbar degenerative disease between 2019 and 2021 with a followup duration greater than 12 months were analyzed. Radiological parameters were measured including psoas muscle volume, total psoas area index (total psoas muscle area [cm2]/height squared [m2]), distance from the iliac artery to the origin of the psoas muscle (DIAPM), angle between the origin of the psoas muscle and the center of the vertebral disc (APCVD), iliac crest height, disc height, lumbar flexibility (lumbar flexion angle minus extension angle), cage location ratio, cage-induced segmental lumbar lordosis (LL) (postoperative index level segmental LL minus used cage angle), foraminal height changes, fusion grade. Results : DIAPM, APCVD, iliac crest height, postoperative index level segmental LL, and cage-induced segmental LL were significantly correlated with OLIF cage obliquity angle. However, other radiological parameters did not correlate with cage obliquity. Based on multiple regression analysis, the predictive equation for the OLIF cage obliquity angle was 13.062–0.318×DIAPM+0.325×A PCVD+0.174×iliac crest height. The greater the cage obliquity, the smaller the segmental LL compared to the cage angle used. Conclusion : At the L4-L5 level, OLIF cage obliquity was affected by DIAPM, APCVD, and iliac crest height, and as the cage obliquity angle increases, LL agnle achievable by the used cage could not be obtained.
Jang, Ji Eun,Cheong, June-Won,Kim, Soo-Jeong,Cho, Hyunsoo,Suh, Cheolwon,Lee, Hyewon,Eom, Hyeon-Seok,Yhim, Ho-Young,Lee, Won-Sik,Min, Chang-Ki,Lee, Jae Hoon,Park, Joon Seong,Kim, Jin Seok Informa UK (Informa Healthcare) 2016 Leukemia & lymphoma Vol.57 No.6
<P>To evaluate the feasibility of selecting a mobilization regimen based on the response to induction therapy, we retrospectively analyzed 179 multiple myeloma patients who underwent stem cell mobilization. In comparison with patients who achieved at least a very good partial response (VGPR) to induction therapy and received granulocyte-colony stimulating factor (G-CSF) alone and patients who did not achieve a VGPR and received cyclophosphamide (CY)+G-CSF, treatment-related toxicity was greater and neutrophil engraftment was slower in the CY than the G-CSF group. The rate of requisite mobilization (2.0x10(6)/kg) was similar in both groups. Overall and progression-free survival was not different between patients in the G-CSF group and patients who achieved at least VGPR and received CY+G-CSF. In conclusion, response-adapted selection of a mobilization regimen is appropriate. G-CSF alone should be the preferred treatment for patients who achieved at least a VGPR to induction therapy.</P>
Cheolwon Suh,Sang Hee Kim,Hyo Jung Kim,Geundoo Jang,Eun Kyung Kim,Ok Bae Ko,Shin Kim,Hee Jung Sohn,Jung Shin Lee,Wookun Kim,Jooryung Huh 대한암학회 2005 Cancer Research and Treatment Vol.37 No.5
Purpose: Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin’s lymphoma (NHL). Various clinical parameters-wereevaluated to obtain significant predictors of the outcome following ASCT in patients with NHLMaterials and Methods: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center. Results: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI. Conclusion: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.
Kim, Kwanghyun,Yu, Sunyoung,An, Cheolwon,Kim, Sung-Wook,Jang, Ji-Hyun American Chemical Society 2018 ACS APPLIED MATERIALS & INTERFACES Vol.10 No.18
<P>Solar desalination via thermal evaporation of seawater is one of the most promising technologies for addressing the serious problem of global water scarcity because it does not require additional supporting energy other than infinite solar energy for generating clean water. However, low efficiency and a large amount of heat loss are considered critical limitations of solar desalination technology. The combination of mesoporous three-dimensional graphene networks (3DGNs) with a high solar absorption property and water-transporting wood pieces with a thermal insulation property has exhibited greatly enhanced solar-to-vapor conversion efficiency. 3DGN deposited on a wood piece provides an outstanding value of solar-to-vapor conversion efficiency, about 91.8%, under 1 sun illumination and excellent desalination efficiency of 5 orders salinity decrement. The mass-producible 3DGN enriched with many mesopores efficiently releases the vapors from an enormous area of the surface by heat localization on the top surface of the wood piece. Because the efficient solar desalination device made by 3DGN on the wood piece is highly scalable and inexpensive, it could serve as one of the main sources for the worldwide supply of purified water achieved via earth-abundant materials without an extra supporting energy source.</P> [FIG OMISSION]</BR>
Cho, Min-Chul,Chung, Yousun,Jang, Seongsoo,Park, Chan-Jeoung,Chi, Hyun-Sook,Huh, Jooryung,Suh, Cheolwon,Shim, Hyoeun Williams & Wilkins Co 2018 Medicine Vol.97 No.45
ABSTRACT: The prognostic significances of the germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) types of diffuse large B-cell lymphoma (DLBCL) have been reported to be different. We analyzed the effect of the cell of origin (COO) of bone marrow (BM) involvement in patients with DLBCL who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in a single institute.The subtype of BM involvement was evaluated in 633 patients who were diagnosed with primary DLBCL and had been treated with R-CHOP. BM trephine biopsies were analyzed, and immunohistochemical staining of CD20, CD79a, and CD3 was performed. Additional staining of CD10, Bcl-6, and MUM1 was performed to determine the COO based on a previously reported algorithm.BM involvement was present in 81 patients (12.8%). Among them, 30 patients (37.0%) had GCB-type BM involvement and 51 (63.0%) showed non-GCB-type involvement. Kaplan-Meier survival analysis showed that the non-GCB type had the worst progression-free survival (PFS) and overall survival (OS) (P <.001). In multivariate analysis controlled for the International Prognostic Index (IPI) score, non-GCB type was an independent predictor of PFS (P <.004) and OS (P =.042), whereas GCB type was not a prognostic factor independent of the IPI score.Further prognostication based on the COO of BM involvement is a useful indicator of PFS, independent of IPI score. Accurate staging based on the COO should be included in the examination of BM in DLBCL.
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
Min-Sun Kim,Chan-Jeoung Park,Young-Uk Cho,Seongsoo Jang,Eul Ju Seo,Chan-Sik Park,Jooryung Huh,Ho-Joon Im,Jong Jin Seo,Dok Hyun Yoon,Cheolwon Suh 대한진단검사의학회 2020 Annals of Laboratory Medicine Vol.40 No.1
Background: JL1, a CD43 epitope and mucin family cell surface glycoprotein, is expressed on leukemic cells. An anti-JL1 antibody combined with a toxic substance can have targeted therapeutic effects against JL1-positive leukemia; however, JL1 expression on bone marrow (BM) lymphoma cells has not been assessed using flow cytometry. We investigated JL1 expression on BM lymphoma cells from patients with non-Hodgkin lymphoma (NHL) to assess the potential of JL1 as a therapeutic target. Methods: Patients with BM involvement of mature B-cell (N=44) or T- and natural killer (NK)-cell (N=4) lymphomas were enrolled from May 2015 to September 2016. JL1 expression on BM lymphoma cells was investigated using flow cytometry. Clinical, pathological, and cytogenetic characteristics, and treatment responses were compared according to JL1 expression status. Results: Of the patients with NHL and BM involvement, 37.5% (18/48) were JL1-positive. Among mature B-cell lymphomas, 100%, 38.9%, 33.3%, 100%, and 25.0% of Burkitt lymphomas, diffuse large B-cell leukemias, mantle cell leukemias, Waldenstrom macroglobulinemia, and other B-cell lymphomas, respectively, were JL1-positive. Three mature T- and NK-cell NHLs were JL1-positive. JL1 expression was associated with age (P=0.045), complete response (P=0.004), and BM involvement at follow-up (P=0.017), but not with sex, performance status, the B symptoms, packed marrow pattern, cytogenetic abnormalities, or survival. Conclusions: JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy.
Lee Min Young,Park Chan-Jeoung,Cho Young-Uk,You Eunkyoung,Jang Seongsoo,Seo Eul Ju,Lee Jung-Hee,Yoon Dok Hyun,Suh Cheolwon 대한진단검사의학회 2021 Annals of Laboratory Medicine Vol.41 No.3
Background: Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM. Methods: A total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry. Results: At diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P<0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P=0.001) and after complete remission following chemotherapy (P=0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy. Conclusions: PD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.
( Yong Park ),( Byung Bae Park ),( Ji Yun Jeong ),( Wook Youn Kim ),( Seongsoo Jang ),( Bong Kyung Shin ),( Dong Soon Lee ),( Jae Ho Han ),( Chan-jeoung Park ),( Cheolwon Suh ),( Insun Kim ),( Hyun-so 대한내과학회 2016 The Korean Journal of Internal Medicine Vol.31 No.6
In September 2011, the Korean Society of Hematology Lymphoma Working Party held a nationwide conference to establish a consensus for assessing bone marrow (BM) involvement in patients with lymphoma. At this conference, many clinicians, hematopathologists, and diagnostic hematologists discussed various topics for a uniform consensus in the evaluation process to determine whether the BM is involved. Now that the discussion has matured suffi ciently to be published, we herein describe the consensus reached and limitations in current methods for assessing BM involvement in patients with lymphoma.
Shim, Hyoeun,Oh, Jae-Il,Park, Sang Hyuk,Jang, Seongsoo,Park, Chan-Jeoung,Huh, Jooryung,Suh, Cheolwon,Chi, Hyun-Sook BMJ Publishing Group Ltd 2013 Journal of clinical pathology Vol.66 No.5
<P><B>Background</B></P><P>Bone marrow involvement confers a poor prognosis in patients with diffuse, large, B-cell lymphoma (DLBCL). However, the prognostic significance of concordant and discordant bone marrow involvement in these cases differs. We analysed this further in patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) at a single institute.</P><P><B>Design and Methods</B></P><P>The cytomorphology of bone marrow involvement was evaluated in 632 patients who were diagnosed with DLBCL in primary tissues and had received R-CHOP therapy. Bone marrow trephine biopsies and clot sections were analysed, along with the immunohistochemical analysis of CD20, CD79a and CD3.</P><P><B>Results</B></P><P>Bone marrow involvement was identified in 80 of our DLBCL patient subjects (12.7%). Of these, 32 (40%) showed discordant bone marrow involvement, and 48 (60%) showed concordant involvement. Kaplan–Meier survival analysis showed that progression-free survival and overall survival was poorer in the concordant group (p<0.001). Multivariate analysis, adjusted for the International Prognostic Index score, showed that concordant involvement was an independent predictor of progression-free survival (p<0.001) and overall survival (p=0.011). Discordant involvement was not a negative prognostic factor independent of the International Prognostic Index.</P><P><B>Conclusions</B></P><P>Prognostication based on bone marrow involvement cytomorphology is a useful indicator of progression-free survival and overall survival, independent of the International Prognostic Index score, in DLBCL patients. Accurate staging based on morphology should thus be included in bone marrow examinations of such cases.</P>